CClinicalTrials.gg
CompletedNCT04593953ETLAUpdated Jul 7, 2022

Efficacy of TLIP Block for Postoperative Analgesia of Lumbar Spinal Fusion

An interventional study of TLIP in Lumbar Spinal Fusion, sponsored by CMC Ambroise Paré. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-07.

Sponsored by CMC Ambroise Paré · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Spinal surgery is associated with severe pain in the immediate postoperative period. In a recent study evaluating pain intensity on the first day after surgery in a large range of surgical procedures, among the six most painful surgeries, three were major spinal procedures. Spinal surgery causes an accumulation of several types of pain. Incisional pain results from activation of peripheral nociceptors. Musculoskeletal pain arises from damage to structures, such as bone, ligaments, muscles, intervertebral disks, and zygapophyseal joints. In addition, neuropathic pain arises from compression and damage to nerve roots exiting the spinal canal and sometimes damage to the spinal cord itself.

Postoperative pain management requires multimodal analgesia, combining drugs and injection of a local anesthetic (LA) in order to reduce opioid consumption after surgery. Among regional anesthesia (RA) techniques, the thoraco-lumbar interfascial plane block (TLIP) was considered. It offers an effective and safe analgesia during the first 24h after herniated lumbar disc surgery. Ultrasound-guided TLIP block involves injection of LAs between longissimus and multifidus muscles (spinal lombar muscles). This injection allows to block the dorsal rami of spinal nerves innervating the paravertebral muscles and the vertebrae.

The objective of this study is to evaluate the interest of TLIP block to improve the postoperative analgesia in patients undergoing lumbar spinal fusion surgery.

Read the detailed description

This is a multicenter, randomized, double-blind (participant and care provider assessing outcomes), parallel-group controlled, trial assessing the interest of the association of TLIP block to general anesthesia for postoperative analgesia management in patients undergoing posterior lumbar spinal fusion.

This study compares two groups:

"Control" group: standard general anesthesia. "TLIP" group: standard general anesthesia + TLIP block with an injection of 40 ml of ropivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.

  • General anesthesia

General anesthesia will be standardized in the two groups:

  • Induction with propofol 2-3 mg/kg, sufentanyl 0.2-0.3 µg/kg and ketamine 0.3 mg/kg
  • Intubation facilitated according centre's protocol and ventilation performed with 50% oxygen and 50% air in order to maintain normocapnia and normoxia.
  • Anesthesia maintained according to the centre's usual care.
  • Prevention of postoperative nausea and vomiting (NVPO) according centre's protocol.

    • TLIP block technique ("TLIP" group only) The regional anesthesia procedure will be performed under general anesthesia and will be guided by ultrasound with high-frequency linear probe, patient in prone position or genupectoral (knee-chest) position. The probe will be positioned in order to have an axial view of lumbar vertebrae. The 3rd lumbar vertebra (L3), the 4th lumbar vertebra (L4) and the 5th lumbar vertebra (L5) will be identified after initial identification of the sacrum. A needle will be inserted in plane (IP) and advanced to reach the interspace between the multifidus and the longissimus muscles on the tip of the articular process. For each patient, the block will be performed bilaterally by injecting of 20 ml of Ropivacaine 0.25% on each side. Before each procedure, a skin disinfection will be carried out using an alcoholic iodine solution.

Patients will not receive any LA by intravenous injection or infiltration.

02

Conditions studied

  • Lumbar Spinal Fusion

Keywords

  • TLIP block
  • Lumbar spinal fusion
  • Regional anesthesia
  • Ropivacaine
  • Postoperative analgesia
  • Ultrasound
  • Pain management
  • Opioids
03

In context

Lead sponsor

CMC Ambroise Paré is the lead sponsor of 47 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ≥ 18 years old,
  • Undergoing posterior lumbar spinal one-level or two-level fusion surgery (L3-L4, L4-L5 and/or L5-S1),
  • Having signed a written informed consent form,
  • Affiliation to the social security system.

Exclusion criteria

Exclusion Criteria:

  • Contraindication for regional anesthesia (allergy to local anesthetics, neuropathic disease, infection at the puncture site, coagulation disorder, refusal of the technique,...)
  • Contraindication to nonsteroidal anti-inflammatory drugs,
  • Patient who have already had a spinal surgery,
  • Patient with chronic pain syndrome (use > 3 months of morphine, opioid analgesics of class 3, pregabalin or gabapentin) or fibromyalgia,
  • A mental or linguistic inability to understand the study,
  • Patient under protection of the adults (guardianship, curators or safeguard of justice),
  • Pregnant or or breastfeeding women.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • No intervention
    CONTROL

    Standard general anesthesia

  • Experimental
    TLIP

    Standard general anesthesia + TLIP block

    Procedure: TLIP

Interventions

  • ProcedureTLIP

    Injection of 40 ml of ropivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.

06

What researchers measure

Primary outcomes

  1. Morphine consumption in the first 24 hours post-surgery

    Total amount of morphine (mg) administered during the first 24 hours post-surgery. The reference time t0 will be the time of skin incision.

    Time frame: 24 hours

Secondary outcomes

  1. Morphine consumption in the first 48 hours post-surgery

    Total amount of morphine (mg) administered during the first 48 hours post-surgery

    Time frame: 48 hours

  2. Morphine consumption in the post-anesthesia care unit (PACU)

    Total amount of morphine (mg) administered in PACU

    Time frame: 6 hours

  3. Duration of postoperative analgesia

    Time (in minutes) between the skin incision (t0) and the first administration of morphine in PACU or in ward.

    Time frame: 48 hours

  4. Postoperative pain: Visual Analogue Scale (VAS)

    Pain scores using a Visual Analogue Scale (VAS) ranging from 0 to 10 (0= no pain; 10= worst imaginable pain). These scores will be recorded before surgery, in PACU and four times a day (morning, afternoon, evening and night) during the first 48 hours post-surgery, both at rest and during exercises (walk with the physiotherapist).

    Time frame: 48 hours

  5. Postoperative quality of recovery

    15-item Quality of Recovery (QoR-15) scale ranging from 0 to 10 (0= very poor recovery; 150= excellent recovery). This multidimensional questionnaire assesses five domains of patient-reported health status: pain, physical comfort, physical independence, psychological support and emotional state.

    Time frame: 72 hours

  6. Side effects associated with opioids

    Incidence of side effects associated with morphine: nausea and vomiting, drowsiness, acute urinary retention.

    Time frame: 72 hours

  7. Rate of complications

    Poor distribution of local anesthetic and rhythm disorders linked to an intravascular injection assessed during regional anesthesia procedure and during the 20 minutes following the block. Infection at the injection site and mechanical complications: hematoma, assessed 72h post-surgery.

    Time frame: 20 minutes, 72 hours

07

Study locations

2 sites
  • CMC Ambroise Paré
    Neuilly-sur-Seine, Ile-de-France 92200, France
  • Hôpital Privé Jean Mermoz
    Lyon, 69008, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04593953
Lead sponsor
CMC Ambroise Paré
Responsible party
Sponsor
First posted
Oct 20, 2020
Start date
Feb 8, 2021
Primary completion
Jun 29, 2022
Completion
Jul 1, 2022
Last update
Jul 7, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion